Viral Hepatitis

• Audio chapter
  Single-voice audio, listen on the commute.
• ABIM-format MCQs
  5-option vignettes with full wrong-answer teaching.
• Study guide
  Tables, decision trees, primary sources.
• AI tutor
  Chapter-grounded, answers the question you're stuck on.

What this chapter covers

• Section 18.1: Acute viral hepatitis phases and differential

  Acute viral hepatitis has the same clinical envelope regardless of the offending virus, which is why reading the serologic panel matters more than reading the symptoms.

• Section 18.2: HBV serology

  HBV serology is the question type in hepatology that gets memorized as a grid because the grid maps directly onto management.

• Section 18.3: HBV treatment and reactivation prevention

  The decision to treat chronic HBV is a multifactorial integration of HBV DNA, ALT, fibrosis stage, and clinical context, and memorizing a single threshold will miss cases.

• Section 18.4: HBV in pregnancy and vertical transmission

  Vertical transmission of HBV is the dominant route by which chronic HBV is acquired worldwide because perinatal infection produces the highest chronicity rate of any age window: 90 percent of neonates infected at birth become chronic carriers, compared with 30 percent of children infected between ages 1 and 5 and only 1 to 5 percent of immunocompetent adults.

• Section 18.5: HCV diagnosis and DAA regimens

  Chronic HCV is now a curable disease, which is the single most consequential change in hepatology over the past decade and the orientation point for every board question on HCV.

• Section 18.6: HCV special populations and post-SVR

  Special populations modify DAA selection because protease inhibitors are hepatically cleared and unsafe in decompensated liver disease, while nucleotide and NS5A inhibitors have distinct renal and drug-interaction profiles.

• Section 18.7: HDV and bulevirtide

  Hepatitis D is a defective negative-stranded RNA virus that requires HBsAg from HBV as its envelope protein, which is why HDV exists only in patients who are also infected with HBV.

• Section 18.8: HAV and HEV

  Hepatitis A is a fecal-orally transmitted picornavirus that produces an acute self-limited illness with an incubation period averaging 28 days, and both the canonical acute presentation and the few atypical presentations are worth recognizing.

Podcast episodes

1. 01

   Oral Viruses

   Episode one of the Viral Hepatitis chapter builds the acute-hepatitis framework and covers the two fecal-oral viruses, hepatitis A and hepatitis E. The organizing idea: acute viral hepatitis looks the same no matter which virus caused it, so you read the virus off the serology, not the symptoms. It walks the four clinical phases, the four-test acute panel with its two named traps, and then hepatitis A as a post-exposure-prophylaxis decision that splits by age and host. Hepatitis E closes it with its two high-yield scenarios: twenty to thirty percent mortality in third-trimester pregnancy and chronic infection in the immunocompromised.

   Read the transcript →
2. 02

   Hepatitis B and D

   Episode two steps inside hepatitis B, where the serologic panel is not just diagnostic but a phase grid that determines treatment, the pregnancy strategy, the reactivation rule, and the hepatitis D testing decision. It reads two grids: the serologic grid of surface antigen, core antibody, and surface antibody that places the patient, and the phase grid of e-antigen, DNA, and ALT that decides whether to treat. From there it covers the nucleoside analogs, the three-pillar pregnancy bundle, the preemptive reactivation prophylaxis rule under immunosuppression, and hepatitis D with its new entry inhibitor bulevirtide. Every threshold, drug, and cutoff is named as the boards test it.

   Read the transcript →
3. 03

   Hepatitis C

   Episode three covers hepatitis C, now a curable disease, and tests the entire workflow of cure: identify the virus, confirm replication, stage the liver, pick the regimen, document cure, then ask the one remaining cancer question. It runs the reflex antibody-then-RNA diagnosis, the two pangenotypic direct-acting antiviral regimens plus the salvage regimen, and a special-populations set built on a few absolute rules. Decompensated cirrhosis forbids protease inhibitors; advanced kidney disease no longer forbids sofosbuvir. It closes on the highest-yield post-cure point: cancer surveillance continues forever in F4 cirrhosis but stops in F3 fibrosis short of cirrhosis.

   Read the transcript →

Key topics

• ·The acute-hepatitis mechanism and its four phases
• ·The four-test first-line serologic panel
• ·Serology interpretation rules and two named traps
• ·Differential, alarm features, and treatment by virus
• ·Hepatitis A course, risk factors, and atypical variants
• ·Hepatitis A vaccine and post-exposure prophylaxis
• ·Hepatitis E genotypes and when to test
• ·Hepatitis E in pregnancy and chronic infection with ribavirin
• ·The six hepatitis B markers and what each means
• ·The serologic grid and the isolated core antibody
• ·The phase grid of chronic infection
• ·Treatment principles, thresholds, and the drug menu
• ·Reactivation under immunosuppression and prophylaxis
• ·Pregnancy: the three-pillar vertical-transmission bundle
• ·Hepatitis D: coinfection versus superinfection
• ·Hepatitis D treatment and bulevirtide
• ·Hepatitis C as a curable disease and the drug classes
• ·The reflex antibody-then-RNA diagnostic algorithm
• ·Universal screening and the pre-treatment workup
• ·The two pangenotypic regimens and the salvage regimen
• ·Sustained virologic response and what cure buys
• ·Decompensated cirrhosis and the protease-inhibitor rule
• ·Kidney disease, transplant, and pregnancy
• ·Post-cure cancer surveillance by fibrosis stage